Health Canada OKs vaccine clinical trial for Ebola disease

By Paul Logothetis

Media Relations Advisor, uOttawa

PPE-clad people in the field
Gani Nurhakim (Unsplash)
Members of the media may directly contact the following uOttawa experts:

Roojin Habibi (English and French)

Assistant Professor, Faculty of Law - Common Law Section and Director of Global Health Law program at the Global Strategy Lab. 

[email protected]

Professor Habibi Roojin  is a Senior Visiting Fellow of the United Nations University’s International Institute for Global Health. Her expertise bridges the fields of international law, health law and human rights, including examining how international law responds to emerging global health risks.

"This phase 1 clinical trial is an important initiative in the global effort to stem the spread of the Bundibugyo virus. But we have to remember that effective medical countermeasures are currently most needed in Democratic Republic of Congo (DRC). What remains unclear, however, is how Canada will contribute to the global effort to help DRC weather this crisis by ensuring access to an effective vaccine - if one is eventually developed."

Earl Brown (English only)

Emeritus Professor, Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine.

[email protected]

Dr. Brown's expertise relates to virology, infectious diseases, respiratory viruses, RNA viruses, microbiology.